IS8128A - Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða - Google Patents

Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða

Info

Publication number
IS8128A
IS8128A IS8128A IS8128A IS8128A IS 8128 A IS8128 A IS 8128A IS 8128 A IS8128 A IS 8128A IS 8128 A IS8128 A IS 8128A IS 8128 A IS8128 A IS 8128A
Authority
IS
Iceland
Prior art keywords
methyl
phenyl
carboxylic acid
paroxetine
trifluoro
Prior art date
Application number
IS8128A
Other languages
English (en)
Icelandic (is)
Inventor
Melotto Sergio
Corsi Mauro
Carletti Renzo
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS8128A publication Critical patent/IS8128A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8128A 2003-04-17 2005-11-15 Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða IS8128A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments
PCT/EP2004/004126 WO2004091624A1 (fr) 2003-04-17 2004-04-16 Combinaison comprenant paroxetine et 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete

Publications (1)

Publication Number Publication Date
IS8128A true IS8128A (is) 2005-11-15

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
IS8128A IS8128A (is) 2003-04-17 2005-11-15 Samsetningar sem fela í sér paroxetín og 2-(S)-(4-flúor-2-metýl-fenýl)-píperasín-1-karboxýlsýru[1-(R)-(3,5-bis-tríflúor-2-metýl-fenýl)-etýl]-metýl-amíð til að meðhöndla þunglyndi og/eða kvíða
IS8129A IS8129A (is) 2003-04-17 2005-11-15 Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS8129A IS8129A (is) 2003-04-17 2005-11-15 Samsetningar paroxetíns og 4-(S)-(4-asetýl-píperasín-1-ýl)-2-(R)-(4-flúor-2-metýl-fenýl)-píperídín-1-karboxýlsýru [1-(R)-(3,5-bis-tríflúormetýl-fenýl)etýl]-metýlamíðs til að meðhöndla þunglyndi og/eða kvíða

Country Status (18)

Country Link
US (4) US20060241143A1 (fr)
EP (4) EP1653956A1 (fr)
JP (4) JP2006523651A (fr)
KR (2) KR20060003876A (fr)
CN (2) CN1809355A (fr)
AU (2) AU2004229181A1 (fr)
BR (2) BRPI0409377A (fr)
CA (2) CA2522311A1 (fr)
CO (1) CO5700753A2 (fr)
GB (1) GB0308968D0 (fr)
IS (2) IS8128A (fr)
MA (2) MA27731A1 (fr)
MX (2) MXPA05011064A (fr)
NO (2) NO20055367L (fr)
PL (2) PL377858A1 (fr)
RU (2) RU2005135647A (fr)
WO (4) WO2004091616A1 (fr)
ZA (2) ZA200508067B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (fr) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Forme dosifee stable d'un antidepresseur
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
WO2012175434A1 (fr) * 2011-06-20 2012-12-27 Glaxo Group Limited Formulations pharmaceutiques comprenant du vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU735760B2 (en) * 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
JP2003522739A (ja) * 1999-12-17 2003-07-29 シェーリング コーポレイション 選択的ニューロキニンアンタゴニスト
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
EP1451153B1 (fr) * 2001-11-13 2007-09-26 Schering Corporation Antagonistes de nk1
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
GB0308968D0 (en) 2003-05-28
EP1615642A1 (fr) 2006-01-18
CN1809359A (zh) 2006-07-26
JP2006523652A (ja) 2006-10-19
WO2004091617A1 (fr) 2004-10-28
PL377857A1 (pl) 2006-02-20
US20060241124A1 (en) 2006-10-26
CA2522313A1 (fr) 2004-10-28
CA2522311A1 (fr) 2004-10-28
MXPA05011064A (es) 2006-04-18
MA27731A1 (fr) 2006-01-02
EP1613325A1 (fr) 2006-01-11
NO20055367L (no) 2005-11-14
US20060217395A1 (en) 2006-09-28
AU2004229181A1 (en) 2004-10-28
IS8129A (is) 2005-11-15
US20060241143A1 (en) 2006-10-26
WO2004091624A1 (fr) 2004-10-28
JP2006523649A (ja) 2006-10-19
US20060287325A1 (en) 2006-12-21
EP1615641A1 (fr) 2006-01-18
WO2004091616A1 (fr) 2004-10-28
ZA200508067B (en) 2007-02-28
JP2006523651A (ja) 2006-10-19
CO5700753A2 (es) 2006-11-30
MA27730A1 (fr) 2006-01-02
BRPI0409379A (pt) 2006-04-25
BRPI0409377A (pt) 2006-04-25
EP1653956A1 (fr) 2006-05-10
ZA200508068B (en) 2007-02-28
CN1809355A (zh) 2006-07-26
JP2006523650A (ja) 2006-10-19
KR20060003876A (ko) 2006-01-11
WO2004091615A1 (fr) 2004-10-28
AU2004229179A1 (en) 2004-10-28
MXPA05011063A (es) 2005-12-12
RU2005135647A (ru) 2006-06-10
KR20060003875A (ko) 2006-01-11
NO20055368L (no) 2005-11-14
PL377858A1 (pl) 2006-02-20
RU2005135649A (ru) 2006-03-20

Similar Documents

Publication Publication Date Title
IS8214A (is) 3,5 tvísetin indasól enfasambönd, lyfjasamsetningar, og aðferðir til að miðla eða hindra frumufjölgun
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
DE602005011795D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
DK1537759T3 (da) Fremgangsmåde til at modvirke okklusionseffekter
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
EP2168578A3 (fr) Composés à base de thiazole présentant une activité inhibitrice enzymatique utilisant de l'adenosine triphosphate (atp)
ATE361279T1 (de) N-[phenyl(piperidin-2-yl)methyl]benzamidderivat , verfahren zu ihrer herstellung und ihre therapeutische anwendung
EP1827436A4 (fr) Inhibiteurs d'activite akt
IS7483A (is) Bensamíðafleiður gagnlegar sem históndeasetýlasatálmar
EP1911757B8 (fr) Procédé de préparation de 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes et thiochromanes en tant que inhibiteurs de la dopamine-beta-hydroxylase
NO20052469D0 (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
DE60217363D1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen-abhängigen erkrankungen
EP1620095A4 (fr) Inhibiteurs de l'activite akt
EP1608225A4 (fr) Interventions chirurgicales thermiques et compositions associees
WO2008016759A3 (fr) Produits anti-âge comprenant des extraits de feuilles de menyanthes trifoliata et procédés d'utilisation de ceux-ci
IL162895A0 (en) Benzamides and compositions benzamides for use as fungicide
NO20050652L (no) Pyrrolidone derivater som maob inhibitorer
FI20021660L (fi) Hiilihydraattien uusi käyttö ja koostumukset
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
AU2003286474A8 (en) Compositions, solutions, and methods used for transplantation
WO2004064832A3 (fr) Methodes pour traiter les douleurs articulaires ou ameliorer le sommeil a l'aide d'un agoniste/antagoniste des oestrogenes
IL176515A0 (en) 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
PL377858A1 (pl) Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluoro-2-metylo-fenylo)-etylo]-metyloamidu kwasu 2-(S)-(4-fluoro-2-metylofenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków
ATE373648T1 (de) Nf-kappab-inhibitoren